Skip to main content

CAR

2
Pipeline Programs
1
Companies
5
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Cell Therapy
1100%
+ 4 programs with unclassified modality

Competitive Landscape

1 companies ranked by most advanced pipeline stage

BioTherapeutics Inc
BioTherapeutics IncVA - Blacksburg
5 programs
2
CD19/CD20 CAR-T cell infusionPhase 1Cell Therapy1 trial
Chimeric antigen receptor modified γδ T cellsPhase 11 trial
Chimeric antigen receptor T cellsN/A1 trial
TAA05 cell injectionN/A1 trial
Targeting CD276 autologous chimeric antigen receptor T cellsN/A1 trial
Active Trials
NCT04692948Unknown5Est. Dec 2023
NCT05017883Unknown5Est. Oct 2025
NCT04691713Unknown5Est. Dec 2021
+2 more trials

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
BioTherapeutics IncChimeric antigen receptor modified γδ T cells
BioTherapeutics IncCD19/CD20 CAR-T cell infusion
BioTherapeutics IncTAA05 cell injection
BioTherapeutics IncChimeric antigen receptor T cells
BioTherapeutics IncTargeting CD276 autologous chimeric antigen receptor T cells

Clinical Trials (5)

Total enrollment: 53 patients across 5 trials

NCT04702841BioTherapeutics IncChimeric antigen receptor modified γδ T cells

CAR - γ δ T Cells in the Treatment of Relapsed and Refractory CD7 Positive T Cell-derived Malignant Tumors

Start: Jun 2020Est. completion: Dec 20228 patients
Phase 1Unknown
NCT04700319BioTherapeutics IncCD19/CD20 CAR-T cell infusion

CAR-T CD19/CD20 for Patients With Advanced CD19/CD20+ B Cell Line Recurrent or Refractory Hematological Malignancies

Start: Apr 2019Est. completion: Jun 202130 patients
Phase 1Unknown
NCT05017883BioTherapeutics IncTAA05 cell injection

TAA05 Cell Injection in the Treatment of Recurrent / Refractory Acute Myeloid Leukemia

Start: Jul 2021Est. completion: Oct 20255 patients
N/AUnknown
NCT04692948BioTherapeutics IncChimeric antigen receptor T cells

TAA6 Cell Injection In The Treatment of Patients With Relapsed / Refractory Acute Myeloid Leukemia

Start: Dec 2019Est. completion: Dec 20235 patients
N/AUnknown
NCT04691713BioTherapeutics IncTargeting CD276 autologous chimeric antigen receptor T cells

CD276 CAR-T for Patients With Advanced CD276+ Solid Tumors

Start: Sep 2019Est. completion: Dec 20215 patients
N/AUnknown

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.